Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
复制标题
DOI：
10.1186/s10194-019-1018-8
复制
发表时间：
2019-06-03
影响因子：
7.4
通讯作者：
Reuter, Uwe
中科院分区：
文献类型：
--
作者：
Raffaelli, Bianca;Mussetto, Valeria;Reuter, Uwe
研究背景针对CGRP通路的单克隆抗体（monoclonal antibodies，mAb）是一种安全有效的治疗偏头痛的药物。在这项研究中，我们评估了预防性erenumab和galcanezumab治疗慢性偏头痛患者的效果中止。MethodsThis回顾性汇总分析包括完成者的开放标签扩展研究阶段的预防性治疗慢性偏头痛与galcanezumab（NCT 02614261; 9个月）和erenumab（NCT 02174861; 12个月）在一个单一的头痛中心。我们比较了开放标签治疗完成后第12周的偏头痛数据，当时患者没有任何预防性药物，研究双盲试验期的基线值，以及开放标签扩展期的最后4周。评估包括每月偏头痛天，头痛小时，严重头痛和急性头痛药物use.ResultsData从16例患者后galcanezumab（n=9）和erenumab（n=7）开放标签治疗完成的变化进行了分析。基线时每月平均偏头痛天数为18.38 ± 3.74天，开放标签扩展期最后4周为12.19 ± 4.53天（p
BackgroundMonoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine. In this study we assessed the effects of discontinuation of preventive erenumab and galcanezumab treatment in patients with chronic migraine.MethodsThis retrospective pooled analysis included completers of the open-label extension study phase for the preventive treatment of chronic migraine with galcanezumab (NCT02614261; 9months) and erenumab (NCT02174861; 12months) in a single headache center. We compare migraine data until week 12 after open-label treatment completion, when patients did not have any pharmacological preventive medication, to study baseline values of the double-blind trial period, and to the last 4weeks of the open-label extension. The assessment included changes in monthly migraine days, headache hours, days with severe headache and acute headache medication use.ResultsData from 16 patients after galcanezumab (n=9) and erenumab (n=7) open-label treatment completion were analyzed. The mean number of monthly migraine days was 18.383.74 at baseline, and 12.19 +/- 4.53 in the last 4weeks of the open-label extension (p